Deciphera Pharmaceuticals
As of the edition of 20 October 2026, Deciphera Pharmaceuticals runs 8 drugs, 2 of them marketed; it is on route A at 7 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Deciphera Pharmaceuticals was renamed in 2017.
The records place 2 company names in this family.
- DECIPHERA PHARMACEUTICALS LLC: renamed in 2017
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 3 |
| Stopped | 3 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ripretinib | Ends 2034 (patent) | 2 |
| Vimseltinib | Ends 2044 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 7 targets, route B at 3 targets.
All 10 rows on route A or B
In the product10 company-target rows on route A or B; 7 are not shown here, and no score is.
See all 10 targets where Deciphera Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 17 trials led
- Digestive system: 9 trials led
- Lungs and airways: 4 trials led